The results of enhanced control in a hypertension and thrombolysis stroke study showed that low-dose tPA led to a lower risk for intracranial hemorrhage compared to the standard dose (0.9 mg/kg) and that low dose tPA reduces mortality rates (21). This evidence concerns the gene PLAT and intracranial hemorrhage.